Nektar Therapeutics Announces Third Quarter 2026 Financial Results
PR Newswire•12/11/2026•16:15 ET
0
Key Highlights
- ➤Cash and investments $952.9M, up from $245.8M at December 31, 2025
- ➤Rezpegaldesleukin Phase 3 ZENITH AD program initiated all three registrational trials
- ➤ZENITH AA registrational trial in alopecia areata expected to begin December 2026
- ➤Q3 revenue $9.4M, down from $11.8M year over year
- ➤Q3 net loss $55.7M; R&D expense rose to $44.1M from $27.3M
Expert Statements
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics
“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development.”
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics
“We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.”
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics
“The strong body of clinical and translational data generated to-date for rezpegaldesleukin reinforce our conviction in its novel and differentiated Treg mechanism, which targets multiple inflammatory pathways that underpin chronic autoimmune disease.”
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics
“We believe rezpegaldesleukin has the potential to offer an important new therapeutic approach for patients, and we're focused on advancing to our topline data readouts in the summer of 2028 with the first BLA filing in 2029.”
Nektar Therapeutics Announces Third Quarter 2026 Financial Results PR Newswire
SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.